slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 41,851-41,880
Pages 2,019
Rows per page 30
Component
41,851-41,880 of 60,557
12
The slide uses icons to categorize milestones into Organization, Fuel cell, and Vehicle.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
15
The table includes both GAAP financial metrics and supplemental non-GAAP/operational data.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
17
The table includes footnotes explaining specific adjustments to the figures.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
19
The table includes adjustments for fair value changes, stock-based compensation, and legal/regulatory matters.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
05
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and therapy type (CAR-T vs TSTx).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
The slide uses a matrix structure to compare clinical outcomes against three key value propositions.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
14
Includes a comparison table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
The table uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
19
The slide uses a red dashed box to highlight the key efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
20
The table displays clinical trial data for NXC-201, including toxicity management metrics like Tocilizumab and Dexamethasone usage.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
21
The slide highlights specific safety data points for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
22
The slide uses a structured table-like layout to map clinical progress against specific disease indications.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
31
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The chart visualizes a single data point (4 months mPFS at 100% of patients with >=3 prior lines of therapy) as a highlighted marker.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
06
The table uses a standard pharmaceutical pipeline layout with clinical and preclinical segments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & Complication1 hit
15
The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
07
The slide uses a table structure to contrast standard of care with the company's target segment. The bottom section uses bar charts to imply relative patient population growth.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
08
The slide explicitly warns about cross-trial comparison limitations in the footer.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
11
Includes a footer citing FDA approval precedents for similar patient population sizes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
18
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a comparison table framework to highlight NXC-201's competitive advantage in safety (lower ICANS/CRS) and efficacy (higher ORR/CR).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
25
The table highlights clinical safety data for NXC-201, showing low incidence of severe adverse events.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
26
The slide highlights specific safety metrics for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
Includes a footer citing FDA approval precedents for patient population sizes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide uses a bubble chart to map mPFS against patient treatment history and a table to detail clinical outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
The chart visualizes a single data point (4 months mPFS at 100% pre-treated status) while the table provides detailed clinical trial outcomes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
49
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit